人源性肿瘤异种移植模型在胰腺癌研究中的应用

Application of patient derived tumor xenograft models in pancreatic cancer research

胰腺癌是一种恶性程度极高,发病隐匿,预后极差的恶性肿瘤,目前以化疗为代表的全身综合治疗仍是改善胰腺癌患者术后预后的主要手段。但胰腺癌耐药机制复杂,可选择的化疗方案较多,患者对每种化疗方案的敏感性不同,疗效也不同,因此需要一种临床前模型检测每种化疗药物的有效性,为患者筛选出最合适的药物。人源性肿瘤异种移植(PDX)通过将患者肿瘤组织植入到免疫缺陷鼠体内从而获得个体化肿瘤模型,指导患者临床用药。本文将在回顾胰腺癌PDX模型建立方法的基础上,对PDX模型在胰腺癌治疗领域的应用进展进行综述,旨在为胰腺癌的个体化治疗提供新的方向。

Pancreatic cancer is a malignant tumor with a high degree of malignancy,insidious onset and very poor prognosis,and the systemic comprehensive treatment represented by chemotherapy is still the main means to im-prove the postoperative prognosis of pancreatic cancer patients.However,the drug resistance mechanism of pancreatic cancer is complex,there are many chemotherapy regimens to choose from,and patients have different sensitivities and efficacy of each chemotherapy regimen,so a preclinical model is needed to test the effectiveness of each chemotherapy drug and screen out the most suitable drug for patients.By implanting the patient's tumor tissue into immunodeficient mice to generate an individualized patient derived tumor xenografts model,the patient is guided to clinical medication.Based on reviewing the PDX model establishment method for pancreatic cancer,this article will review the application progress of PDX model in the field of pancreatic cancer treatment,aiming to provide a new direction for the individual-ized treatment of pancreatic cancer.